284 related articles for article (PubMed ID: 26729897)
21. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
[TBL] [Abstract][Full Text] [Related]
22. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival.
Shepherd P; Suffolk R; Halsey J; Allan N
Br J Haematol; 1995 Mar; 89(3):546-54. PubMed ID: 7734353
[TBL] [Abstract][Full Text] [Related]
23. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
24. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
25. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
Saglio G; Pane F; Gottardi E; Frigeri F; Buonaiuto MR; Guerrasio A; de Micheli D; Parziale A; Fornaci MN; Martinelli G; Salvatore F
Blood; 1996 Feb; 87(3):1075-80. PubMed ID: 8562932
[TBL] [Abstract][Full Text] [Related]
26. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
27. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
[TBL] [Abstract][Full Text] [Related]
28. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
[TBL] [Abstract][Full Text] [Related]
29. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Sharma P; Kumar L; Mohanty S; Kochupillai V
Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
[TBL] [Abstract][Full Text] [Related]
30. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
31. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
32. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
33. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
34. Distribution of
Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
[TBL] [Abstract][Full Text] [Related]
35. Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene.
Dmytrenko IV; Fedorenko VG; Shlyakhtychenko TY; Sholoyko VV; Lyubarets TF; Malinkina TV; Dmytrenko OO; Balan VV; Kravchenko SM; Martina ZV; Tovstogan AO; Minchenko JM; Dyagil IS
Probl Radiac Med Radiobiol; 2015 Dec; 20():328-40. PubMed ID: 26695912
[TBL] [Abstract][Full Text] [Related]
36. A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.
Zenebe B; Nigussie H; Belay G; Seboka N
Hematology; 2023 Dec; 28(1):2284038. PubMed ID: 37982440
[TBL] [Abstract][Full Text] [Related]
37. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
Am J Hematol; 2012 Aug; 87(8):760-5. PubMed ID: 22641468
[TBL] [Abstract][Full Text] [Related]
38. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
[TBL] [Abstract][Full Text] [Related]
39. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
40. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
Burmeister T; Reinhardt R
Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
